EUVIMEDEUVIMED entdecken
Crossref

Long‐term outcomes of renal AL amyloidosis patients undergoing autologous stem cell transplantation: Validating the performance of the renal staging system

Eli Muchtar iD, Morie A Gertz iD, Raphael Mwangi, Hamza Hassan iD, Angela Dispenzieri iD, Nelson Leung iD, Francis K Buadi, David Dingli, Andrew Staron, Vaishali Sanchorawala iD

American Journal of Hematology · 2024

DOI: 10.1002/ajh.27460 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Hematology, 2024. Verfasst von Eli Muchtar und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA. Hauptthemen laut MEDLINE: Immunoglobulin Light-chain Amyloidosis, Transplantation, Autologous, Kidney Failure, Chronic. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 29 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Renal AL amyloidosis can be complicated by end‐stage renal disease (ESRD) requiring renal replacement therapy (RRT). In this study, we describe the long‐term outcomes of renal AL amyloidosis patients undergoing autologous stem cell transplantation (ASCT) and assess the utility of the renal staging system. Retrospective study of renal AL patients ( n = 697; Mayo Clinic, Boston University) who underwent ASCT between 2003 and 2020. Renal stage was assigned based on 24‐h proteinuria and estimated glomerular filtration rate measurements. Renal survival was defined as the time from ASCT until initiation of RRT, while patients who were not placed on RRT were censored at their last follow‐up. With a median follow‐up of 10.4 years, RRT was required in 149 patients (21%). The median time from ASCT to ESRD was 3.4 years, with late events of progression to ESRD seen >10 years from ASCT. Pre‐ASCT renal stage was significantly associated with the cumulative incidence of RRT: 3‐year RRT rate was 3%, 10%, and 37% for renal stages I, II, and III, respectively. However, in the 2012–2020 period subset, a significant decrease in ESRD risk was noted across all renal stages (3‐year RRT 0%, 5%, and 24%, respectively). In multivariate analysis, renal survival was independently associated with the pre‐ASCT renal stage, lambda isotype, bone marrow plasmacytosis ≥20%, post‐ASCT hematologic response, and year of ASCT. Long‐term outcomes of renal AL amyloidosis treated with ASCT are presented. Renal stage reliably predicts renal outcomes in patients with AL undergoing ASCT, despite a reduction in the proportion of patients progressing to RRT in recent years.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immunoglobulin Light-chain AmyloidosisTransplantation, AutologousKidney Failure, ChronicHumansMaleFemaleMiddle AgedRetrospective StudiesAgedAdultHematopoietic Stem Cell TransplantationRenal Replacement TherapyTreatment OutcomeGlomerular Filtration RateFollow-Up Studies

Autor:innen und Institutionen

  • Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA.
  • Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.
  • Amyloidosis Center, Boston University Chobanian & Avedisian School of Medicine and Boston Medical Center, Boston, Massachusetts, USA.
  • Division of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota, USA.

ORCID-Profile: Eli Muchtar, Morie A Gertz, Hamza Hassan, Angela Dispenzieri, Nelson Leung, Vaishali Sanchorawala

Zitieren

APA

Muchtar, E., Gertz, M. A., Mwangi, R., Hassan, H., Dispenzieri, A., Leung, N., Buadi, F. K., Dingli, D., Staron, A., & Sanchorawala, V. (2024). Long‐term outcomes of renal AL amyloidosis patients undergoing autologous stem cell transplantation: Validating the performance of the renal staging system. American Journal of Hematology. https://doi.org/10.1002/ajh.27460

Vancouver

Muchtar E, Gertz MA, Mwangi R, Hassan H, Dispenzieri A, Leung N, et al. Long‐term outcomes of renal AL amyloidosis patients undergoing autologous stem cell transplantation: Validating the performance of the renal staging system. American Journal of Hematology. 2024. doi:10.1002/ajh.27460

BibTeX
@article{Muchtar2024,
  author = {Muchtar, Eli and Gertz, Morie A and Mwangi, Raphael and Hassan, Hamza and Dispenzieri, Angela and Leung, Nelson and Buadi, Francis K and Dingli, David and Staron, Andrew and Sanchorawala, Vaishali},
  title = {Long‐term outcomes of renal AL amyloidosis patients undergoing autologous stem cell transplantation: Validating the performance of the renal staging system},
  journal = {American Journal of Hematology},
  year = {2024},
  doi = {10.1002/ajh.27460}
}
Kostenlos starten →